Patent application number | Description | Published |
20080269467 | Anti-IL-17 Antibodies - Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders. | 10-30-2008 |
20100015155 | PEGYLATED ABETA FAB - A method to treat conditions associated with Aβ peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human Aβ peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule. | 01-21-2010 |
20100129369 | c-Met Antibodies - Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met. | 05-27-2010 |
20110027290 | ANTI-IL-17 ANTIBODIES - Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders. | 02-03-2011 |
20120263723 | c-Met Antibodies - Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met. | 10-18-2012 |
20130142806 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - The present invention provides anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease. | 06-06-2013 |
20130280256 | ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM). | 10-24-2013 |
20130324474 | VARIANTS OF HUMAN GDNF - The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use. | 12-05-2013 |
20140065138 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - The present invention provides anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof for the treatment of Alzheimer's disease. | 03-06-2014 |
20140255406 | ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES - Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFα) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS). | 09-11-2014 |
20140349310 | Anti-c-Met Antibodies - Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis. | 11-27-2014 |